Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Trial details
- Registry ID
- NCT05256290
- Phase
- Phase 1, Phase 2
Drug identity checked against registry records
Also recorded as BDTX-1535
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsNCT05256290 | BDTX | Phase 1, Phase 2 | Recruiting | 2028-03Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |